Please use this identifier to cite or link to this item:
|Title:||Azo dyes and the blood-brain barrier: Robert Aird's novel concept in chronic neurological disease (1903-2000).|
|Authors:||Bladin, Peter F|
|Affiliation:||Comprehensive Epilepsy Program, Austin Health, Heidelberg, Melbourne, VIC 3084, Australia. Electronic address: email@example.com.|
|Citation:||Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia 2013; 21(1): 33-9|
|Abstract:||The well-established medical involvement of derivatives of the azo dye industry lent credibility to the 1935 announcement by Stanley Cobb of the use of vital brilliant red dye as an anticonvulsant. Although in the fullness of time clinical experience would discard this concept, nevertheless it was to give rise to Robert Aird who posited that the mechanism of action of this dye was due to its ability to decrease the permeability of the blood-brain barrier. In a very prolonged exploration of this concept, Aird concluded that blood-brain barrier permeability underlay the causation of a long list of chronic neurological conditions--a concept that was eventually abandoned. This article examines the details and the effects of this concept and its impact upon neurology.|
|Internal ID Number:||24238829|
Chronic neurological condition
Blood-Brain Barrier.drug effects
History, 20th Century
History, 21st Century
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.